Rapid phenotypic assay for human immunodeficiency virus type 1 protease using in vitro translation

Journal of Virological Methods

Volumn 106, Issue 1, 2002, Pages 25-37

  Iga, Mutsunori ^a   Matsuda, Zene ^b   Okayama, Akihiko ^a   Sugiura, Wataru ^b   Hashida, Seiichi ^a   Morishita, Kazuhiro ^a   Nagai, Yoshiyuki ^b   Tsubouchi, Hirohito ^a  

^a UNIVERSITY OF MIYAZAKI   (Japan)

^b NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

HIV 1; In vitro translation; Phenotypic assay; Protease

Indexed keywords

GAG PROTEIN; INDINAVIR; NELFINAVIR; POL PROTEIN; PROTEINASE; RNA DIRECTED DNA POLYMERASE;

ANTIBIOTIC RESISTANCE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG SENSITIVITY; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; EVALUATION; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; IN VITRO STUDY; MUTAGENESIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RABBIT; RETICULOCYTE;

ANIMALS; DRUG RESISTANCE, VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FUSION PROTEINS, GAG-POL; HIV PROTEASE; HIV PROTEASE INHIBITORS; HUMANS; INDINAVIR; INHIBITORY CONCENTRATION 50; MICROBIAL SENSITIVITY TESTS; NELFINAVIR; PHENOTYPE; PROTEIN BIOSYNTHESIS; RABBITS; RETICULOCYTES; TIME FACTORS; TRANSCRIPTION, GENETIC;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; ORYCTOLAGUS CUNICULUS;

EID: 0036803368     PISSN: 01660934     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-0934(02)00133-7     Document Type: Article

References (27)

1. Carpenter C.C., Fischl M.A., Hammer S.M., Hirsch M.S., Jacobsen D.M., Katzenstein D.A., Montaner J.S., Richman D.D., Saag M.S., Schooley R.T., Thompson M.A., Vella S., Yeni P.G., Volberding P.A. Antiviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society, USA Panel. J. Am. Med. Assoc. 277:1997;1962-1969.
2. Cohen C., Kessler H., Hunt S., Sension M., Farthing C., Conant M., Jacobson S., Nadler J., Verbiest W., Hertogs K., Ames M., Rinehart A., Graham N. Phenotypic resistance testing significantly improves response to therapy: final analysis of a randomized trial (VIRA3001). Antiviral Therapy. 5:2000;67.
3. Collier A.C., Coombs R.W., Schoenfeld D.A., Bassett R.L., Timpone J., Baruch A., Jones M., Facey K., Whitacre C., McAuliffe V.J., Friedman H.M., Merigan T.C., Reichman R.C., Hooper C., Corey L. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. New Engl. J. Med. 334:1996;1011-1017.
4. Condra J.H., Holder D.J., Schleif W.A., Blahy O.M., Danovich R.M., Gabryelski L.J., Graham D.J., Laird D., Quintero J.C., Rhodes A., et al. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J. Virol. 70:1996;8270-8276.
5. Durant J., Clevenbergh P., Halfon P., Delgiudice P., Porsin S., Simonet P., Montagne N., Boucher C.A., Schapiro J.M., Dellamonica P. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomized controlled trial. Lancet. 353:1999;2195-2199.
6. Hashida S., Hashinaka K., Nishikata I., Saito A., Takamizawa A., Shinagawa H., Ishikawa E. Ultrasensitive and more specific enzyme immunoassay (immunecomplex transfer enzyme immunoassay) for p24 antigen of HIV-1 in serum using affinity-purified rabbit anti-p24 Fab′ and monoclonal mouse anti-p24 Fab′ J. Clin. Lab. Anal. 10:1996;302-307.
7. Havlir D.V., Eastman S., Gamst A., Richman D.D. Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients. J. Virol. 70:1996;7894-7899.
8. Hertogs K., de Bethune M.P., Miller V., Ivens T., Schel P., Van Cauwenberge A., Van Den Eynde C., Van Gerwen V., Azijn H., Van Houtte M., Peeters F., Staszewski S., Conant M., Bloor S., Kemp S., Larder B., Pauwels R. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob. Agents Chemother. 42:1998;269-276.
9. Hirsch M.S., Conway B., D'Aquila R.T., Johnson V.A., Brun-Vezinet F., Clotet B., Demeter L.M., Hammer S.M., Jacobsen D.M., Kuritzkes D.R., Loveday C., Mellors J.W., Vella S., Richman D.D. Antiretroviral drug resistance testing in adults with HIV infection. J. Am. Med. Assoc. 279:1998;1984-1991.
10. Jacobsen H., Hanggi M., Ott M., Duncan I.B., Owen S., Andreoni M., Vella S., Mous J. In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, kinetics, and frequencies. J. Infect. Dis. 173:1996;1379-1387.
11. Japour A.J., Mayers D.L., Johnson V.A., Kuritzkes D.R., Beckett L.A., Arduino J.M., Lane J., Black R.J., Reichelderfer P.S., D'Aquila R.T., et al. Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. Antimicrob. Agents Chemother. 37:1993;1095-1101.
12. Kellam P., Larder B.A. Recombinant virus assay: a rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates. Antimicrob. Agents Chemother. 38:1994;23-30.
13. Kohl N.E., Emini E.A., Schleif W.A., Davis L.J., Heimbach J.C., Dixon R.A., Scolnick E.M., Sigal I.S. Active human immunodeficiency virus protease is required for viral infectivity. Proc. Natl. Acad. Sci. USA. 85:1988;4686-4690.
14. Krausslich H.G., Ingraham R.H., Skoog M.T., Wimmer E., Pallai P.V., Carter C.A. Activity of purified biosynthetic proteinase of human immunodeficiency virus on natural substrates and synthetic peptides. Proc. Natl. Acad. Sci. USA. 86:1989;807-811.
15. Larder B.A., Darby G., Richman D.D. HIV with reduced sensitivity to zidovudine isolated during prolonged therapy. Science. 243:1989;1731-1734.
16. Martinez M.A., Cabana M., Parera M., Gutierrez A., Este J.A., Clotet B. A bacteriophage lambda-based genetic screen for characterization of the activity and phenotype of the human immunodeficiency virus type 1 protease. Antimicrob. Agents Chemother. 44:2000;1132-1139.
17. Martinez-Picado J., Savara A.V., Sutton L., D'Aquila R.T. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1. J. Virol. 73:1999;3744-3752.
18. Matayoshi E.D., Wang G.T., Krafft G.A., Erickson J. Novel fluorogenic substrates for assaying retroviral proteases by resonance energy transfer. Science. 247:1990;954-958.
19. Patick A.K., Mo H., Markowitz M., Appelt K., Wu B., Musick L., Kalish V., Kaldor S., Reich S., Ho D., Webber S. Antiviral and resistance studies of AG1343, an orally bio-available inhibitor of human immunodeficiency virus protease. Antimicrob. Agents Chemother. 40:1996;292-297.
20. Patick A.K., Duran M., Cao Y., Shugarts D., Keller M.R., Mazabel E., Knowles M., Chapman S., Kuritzkes D.R., Markowitz M. Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir. Antimicrob. Agents Chemother. 42:1998;2637-2644.
21. Ratner L., Fisher A., Jagodzinski L.L., Mitsuya H., Liou R.S., Gallo R.C., Wong-Staal F. Complete nucleotide sequences of functional clones of the AIDS virus. AIDS Res. Hum. Retroviruses. 3:1987;57-69.
22. Richman D.D., Havlir D., Corbeil J., Looney D., Ignacio C., Spector S.A., Sullivan J., Cheeseman S., Barringer K., Pauletti D., et al. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J. Virol. 68:1994;1660-1666.
23. Sambrook, J., Fritsch, E.F., Maniatis, T., 1989. Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory, Plainview, NY.
24. Schuurman R., Nijhuis M., van Leeuwen R., Schipper P., de Jong D., Collis P., Danner S.A., Mulder J., Loveday C., Christopherson C., et al. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J. Infect. Dis. 171:1995;1411-1419.
25. Yu S.L., Wang N., Liou C.Y., Syu W.J. Assay of HIV-1 protease activity by use of crude preparations of enzyme and biotinylated substrate. J. Virol. Methods. 53:1995;63-73.
26. Zennou V., Mammano F., Paulous S., Mathez D., Clavel F. Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo. J. Virol. 72:1998;3300-3306.
27. Zybarth G., Carter C. Domains upstream of the protease (PR) in human immunodeficiency virus type 1 gag-pol influence PR autoprocessing. J. Virol. 69:1995;3878-3884.